Using AI to Improve Medication Safety in Older Adults
Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults
This study tests whether an AI tool can help doctors prescribe safer medications for older adults in the hospital to prevent harmful drug interactions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 5 sites (Bordeaux and 4 other locations) |
| Trial ID | NCT04710615 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of the Synapse platform, an artificial intelligence tool designed to assist healthcare providers in prescribing medications for older adults. The study focuses on patients aged 65 and older who are hospitalized in geriatric departments and are prescribed multiple medications. By utilizing the Synapse platform, physicians can quickly assess potential drug-drug interactions and inappropriate prescriptions based on established STOPP criteria. The goal is to reduce the frequency of harmful medication prescriptions and improve patient safety during hospital discharge.
Who should consider this trial
Good fit: Ideal candidates for this study are older adults aged 65 and above who are hospitalized and prescribed at least two active medications.
Not a fit: Patients who are not hospitalized or those with fewer than two active pharmaceutical ingredients in their prescriptions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance medication safety and reduce adverse drug interactions in elderly patients.
How similar studies have performed: Other studies have shown promising results using technology to improve medication management in older adults, indicating potential for success with this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
* Inclusion criteria: * Male or female age aged more than 65 years * Hospitalization in geriatric department at Bordeaux University Hospital or Libourne Hospital * Initial drug prescription with at least 2 active pharmaceutical ingredients * Affiliation to French social security * Written informed consent signed by participant and investigator * Exclusion criteria: * Adults protected by law * Subject included in a clinical trial with an experimental treatment * Subject during exclusion period relative to another trial
Where this trial is running
Bordeaux and 4 other locations
- CHU de Bordeaux, Hôpital Pellegrin — Bordeaux, France (Recruiting)
- CHU de Bordeaux — Bordeaux, France (Recruiting)
- Centre Hospitalier de Libourne - Pôle Gériatrie — Libourne, France (Recruiting)
- CHU de Bordeaux, Hôpital Xavier Arnozan — Pessac, France (Recruiting)
- CHU de Bordeaux, Hôpital Xavier Arnozan — Pessac, France (Recruiting)
Study contacts
- Principal investigator: Pierre-Olivier GIRODET, MD, PhD — University Hospital, Bordeaux
- Study coordinator: Pierre-Olivier GIRODET, MD, PhD
- Email: pierre-olivier.girodet@chu-bordeaux.fr
- Phone: +335 57 57 15 60
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.